uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cardiology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, UCR-Uppsala Clinical Research Center.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Anaesthesiology and Intensive Care.
Show others and affiliations
2014 (English)In: Heart, ISSN 1355-6037, E-ISSN 1468-201X, Vol. 100, no 22, 1762-1769 p.Article in journal (Refereed) Published
Abstract [en]


To describe specific causes of death and evaluate whether bleeding events and infection contributed to mortality in all ticagrelor-treated and clopidogrel-treated patients with acute coronary syndromes.


In the PLATelet inhibition and patient Outcomes (PLATO) trial, ticagrelor significantly reduced rates of vascular and total death compared with clopidogrel. In the 905 patients who died postenrolment in the PLATO trial (n=18 624), reviewers, blinded to study treatment, subclassified direct causes of death and evaluated whether infection or bleeding events contributed to fatal events.


Among vascular deaths, there were significantly fewer sudden deaths (63 (0.7%) vs 98 (1.1%), p<0.01) but no significant difference in deaths caused by acute myocardial infarction (179 (1.9%) vs 194 (2.1%), p=0.43) or heart failure (31 (0.3%) vs 42 (0.5%), p=0.20) with ticagrelor compared with clopidogrel. For non-vascular deaths, there was no difference between treatments in deaths directly caused by infection. Although, patients treated with ticagrelor were at lower risk for death where infection was either a direct cause or contributed to death (51 (0.5%) vs 76 (0.8%), HR 0.67 (0.47 to 0.95), p<0.05) but not for bleeding (42 (0.5%) vs 42 (0.5%), HR 0.99 (0.65 to 1.53), p=0.98).


In this post hoc analysis, ticagrelor compared with clopidogrel reduced total and cardiovascular mortality, which appeared to be mainly mediated by a reduction in sudden death. Importantly, bleeding causing or contributing to death did not differ between treatments.

Clinical trial registration number

NCT00391872 (http://www.clinicaltrial.gov).

Place, publisher, year, edition, pages
2014. Vol. 100, no 22, 1762-1769 p.
National Category
Cardiac and Cardiovascular Systems
URN: urn:nbn:se:uu:diva-236285DOI: 10.1136/heartjnl-2014-305619ISI: 000345450400007PubMedID: 24957530OAI: oai:DiVA.org:uu-236285DiVA: diva2:763749
Available from: 2014-11-17 Created: 2014-11-17 Last updated: 2015-01-05Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Varenhorst, ChristophAlström, UlricaBertilsson, MariaJames, StefanWallentin, LarsHeld, Claes
By organisation
CardiologyUCR-Uppsala Clinical Research CenterAnaesthesiology and Intensive Care
In the same journal
Cardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 275 hits
ReferencesLink to record
Permanent link

Direct link